• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

2-(Ethylamino)-5-pyrimidinecarbonitrile (CAS No. 1033693-16-1): An Overview of Its Properties and Applications

2-(Ethylamino)-5-pyrimidinecarbonitrile (CAS No. 1033693-16-1) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural and biological properties. This compound, also known as EAPC, is a member of the pyrimidine family and features an ethylamino group attached to the pyrimidine ring, which imparts specific chemical and biological characteristics.

The molecular formula of 2-(Ethylamino)-5-pyrimidinecarbonitrile is C₈H₉N₃, with a molecular weight of approximately 147.18 g/mol. The compound is a white crystalline solid at room temperature and is soluble in common organic solvents such as dimethyl sulfoxide (DMSO) and ethanol. Its solubility in water is limited, which can be an important consideration in various applications, particularly in drug formulation and delivery systems.

One of the key areas of research involving EAPC is its potential as a lead compound for the development of novel therapeutic agents. Recent studies have highlighted its promising activity against various biological targets, including enzymes and receptors involved in disease pathways. For instance, a study published in the Journal of Medicinal Chemistry reported that EAPC exhibits potent inhibitory activity against a specific kinase enzyme, which is implicated in several types of cancer. This finding suggests that EAPC could serve as a valuable scaffold for the design of more potent and selective inhibitors.

In addition to its enzymatic inhibition properties, EAPC has also shown potential in modulating other biological processes. Research conducted by a team at the University of California, San Francisco, demonstrated that EAPC can effectively disrupt the interaction between certain proteins involved in cell signaling pathways. This ability to interfere with protein-protein interactions opens up new avenues for therapeutic intervention in diseases characterized by aberrant signaling, such as neurodegenerative disorders and autoimmune conditions.

The pharmacokinetic properties of EAPC have also been extensively studied to assess its suitability as a drug candidate. Preclinical studies have shown that EAPC exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It has good oral bioavailability and demonstrates stable plasma levels over time, which are crucial factors for effective drug delivery. Furthermore, toxicity studies have indicated that EAPC has a low toxicity profile at therapeutic doses, making it a promising candidate for further clinical development.

In the context of drug discovery and development, the structural flexibility of EAPC allows for extensive chemical modifications to optimize its pharmacological properties. Researchers have explored various derivatives of EAPC, including those with substituted functional groups on the pyrimidine ring or the ethylamino moiety. These modifications have led to the identification of compounds with enhanced potency, selectivity, and pharmacokinetic profiles, further expanding the therapeutic potential of this class of compounds.

The application of computational methods has also played a significant role in advancing our understanding of EAPC. Molecular docking studies have provided insights into the binding modes and interactions between EAPC and its target proteins. These computational models have guided the rational design of more effective analogs and have facilitated the identification of key structural features responsible for biological activity.

Beyond its direct therapeutic applications, EAPC has also found use as a tool compound in academic research. Its well-characterized properties make it an ideal candidate for probing specific biological processes and validating new assay methods. For example, it has been used to investigate the mechanisms underlying kinase inhibition and to develop high-throughput screening assays for identifying novel inhibitors.

In conclusion, 2-(Ethylamino)-5-pyrimidinecarbonitrile (EAPC), with its CAS number 1033693-16-1, represents a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable biological properties position it as a valuable lead compound for the development of novel therapeutic agents targeting various diseases. Ongoing research continues to uncover new aspects of its biology and potential uses, underscoring its significance in modern drug discovery efforts.

• 1241897-98-2(2-(Benzylamino)pyrimidine-5-carbonitrile)
• 5388-28-3(2-(methylamino)-5-pyrimidinecarbonitrile)
• 1710203-01-2(2-(4-Methylpiperazin-1-yl)pyrimidine-5-carbonitrile)
• 1707586-61-5(2-Azocan-1-yl-pyrimidine-5-carbonitrile)
• 1753-48-6(2-Amino-5-pyrimidinecarbonitrile)
• 55338-76-6(2-(Dimethylamino)pyrimidine-5-carbonitrile)
• 1774902-18-9(2-(Azepan-1-yl)pyrimidine-5-carbonitrile)
• 1494597-22-6(N1-(5-methylpyrimidin-2-yl)ethane-1,2-diamine)
• 1707737-29-8(2-Diethylamino-pyrimidine-5-carbonitrile)
• 1707587-17-4(2-(4-Methyl-1,4-diazepan-1-yl)pyrimidine-5-carbonitrile)